Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1978 Jul;63(3):509–512. doi: 10.1111/j.1476-5381.1978.tb07805.x

Plasma clearance of neostigmine and pyridostigmine in the dog.

P R Baker, T N Calvey, K Chan, C M Macnee, K Taylor
PMCID: PMC1668085  PMID: 667495

Abstract

1 The pharmacokinetics of neostigmine and pyridostigmine was studied in conscious dogs by the use of a cross-over design. 2 Both neostigmine and pyridostigmine were cleared from plasma in a biexponential manner. 3 The apparent volume of distribution of pyridostigmine was invariably greater than that of neostigmine, and its fast disposition half-life was approximately three times longer. 4 The whole body clearance and the urinary elimination of pyridostigmine was approximately twice that of neostigmine. 5 The slow disposition half-life of pyridostigmine was approximately three times longer than that of neostigmine, suggesting that the longer duration of action of pyridostigmine is related to the differential clearance of the two quarternary amines from plasma.

Full text

PDF
509

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burdfield P. A., Calvey T. N. Plasma clearance of neostigmine and pyridostigmine in rats with ligated renal pedicles. Eur J Pharmacol. 1973 Nov;24(2):252–255. doi: 10.1016/0014-2999(73)90079-4. [DOI] [PubMed] [Google Scholar]
  2. Burdfield P. A., Calvey T. N., Roberts J. B. In vitro metabolism of neostigmine and pyridostigmine. J Pharm Pharmacol. 1973 May;25(5):428–429. doi: 10.1111/j.2042-7158.1973.tb10045.x. [DOI] [PubMed] [Google Scholar]
  3. Chan K., Williams N. E., Baty J. D., Calvey T. N. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J Chromatogr. 1976 May 26;120(2):349–358. doi: 10.1016/s0021-9673(76)80012-x. [DOI] [PubMed] [Google Scholar]
  4. KITZ R. J. HUMAN TISSUE CHOLINESTERASES: RATES OF RECOVERY AFTER INHIBITION BY NEOSTIGMINE; MICHAELIS-MENTEN CONSTANTS. Biochem Pharmacol. 1964 Sep;13:1275–1282. doi: 10.1016/0006-2952(64)90228-x. [DOI] [PubMed] [Google Scholar]
  5. Miller R. D., Van Nyhuis L. S., Eger E. I., 2nd, Vitez T. S., Way W. L. Comparative times to peak effect and durations of action of neostigmine and pyridostigmine. Anesthesiology. 1974 Jul;41(1):27–33. doi: 10.1097/00000542-197407000-00005. [DOI] [PubMed] [Google Scholar]
  6. SMITH C. M., MEAD J. C., UNNA K. R. Antagonism of tubocurarine. III. Time course of action of pyridostigmin, neostigmine, and edrophonium in vivo and in vitro. J Pharmacol Exp Ther. 1957 Jun;120(2):215–228. [PubMed] [Google Scholar]
  7. Somani S. M., Roberts J. B., Wilson A. Pyridostigmine metabolism in man. Clin Pharmacol Ther. 1972 May-Jun;13(3):393–399. doi: 10.1002/cpt1972133393. [DOI] [PubMed] [Google Scholar]
  8. WILSON I. B., HARRISON M. A., GINSBURG S. Carbamyl derivatives of acetylcholinesterase. J Biol Chem. 1961 May;236:1498–1500. [PubMed] [Google Scholar]
  9. Wilson E. B. The inhibition and reactivation of acetylcholinesterase. Ann N Y Acad Sci. 1966 Jan 26;135(1):177–183. doi: 10.1111/j.1749-6632.1966.tb45471.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES